国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2015年
16期
2428-2431
,共4页
黛力新%氟西汀%脑梗死后抑郁%疗效
黛力新%氟西汀%腦梗死後抑鬱%療效
대력신%불서정%뇌경사후억욱%료효
Flupentixol and Melitracen%Fluoxetine%Depression after cerebral infarction%Efficacy
目的 探讨黛力新联合氟西汀对脑梗死后抑郁患者的临床疗效观察.方法 选择2012年4月至2014年4月我院收治的78例脑梗死后抑郁患者,将其随机分为观察组40例、对照组38例,对照组采取氟西汀治疗,观察组在对照组基础上联合运用黛力新治疗,比较两组患者临床疗效、汉密尔顿抑郁量表(HAMD)评分以及神经功能缺损(NIHSS)评分.结果 治疗后总有效率观察组为92.50％,对照组为73.68％,两组比较差异具有统计学意义(x2=4.967,P＜0.05);治疗前两组患者HAMD、NIHSS评分比较差异无统计学意义(P＞0.05),治疗后两组患者HAMD、NIHSS评分均较治疗前显著降低(P＜0.05),且治疗后观察组HAMD、NIHSS评分显著低于对照组(P＜0.05);不良反应发生率观察组为27.50％,对照组为23.68％,两组比较差异无统计学意义(x2=0.101,P＞0.05).结论 黛力新联合氟西汀治疗脑梗死后抑郁症患者具有显著的临床疗效,较单用氟西汀更加有助于患者抑郁症状以及神经功能的恢复,值得临床推广运用.
目的 探討黛力新聯閤氟西汀對腦梗死後抑鬱患者的臨床療效觀察.方法 選擇2012年4月至2014年4月我院收治的78例腦梗死後抑鬱患者,將其隨機分為觀察組40例、對照組38例,對照組採取氟西汀治療,觀察組在對照組基礎上聯閤運用黛力新治療,比較兩組患者臨床療效、漢密爾頓抑鬱量錶(HAMD)評分以及神經功能缺損(NIHSS)評分.結果 治療後總有效率觀察組為92.50％,對照組為73.68％,兩組比較差異具有統計學意義(x2=4.967,P＜0.05);治療前兩組患者HAMD、NIHSS評分比較差異無統計學意義(P＞0.05),治療後兩組患者HAMD、NIHSS評分均較治療前顯著降低(P＜0.05),且治療後觀察組HAMD、NIHSS評分顯著低于對照組(P＜0.05);不良反應髮生率觀察組為27.50％,對照組為23.68％,兩組比較差異無統計學意義(x2=0.101,P＞0.05).結論 黛力新聯閤氟西汀治療腦梗死後抑鬱癥患者具有顯著的臨床療效,較單用氟西汀更加有助于患者抑鬱癥狀以及神經功能的恢複,值得臨床推廣運用.
목적 탐토대력신연합불서정대뇌경사후억욱환자적림상료효관찰.방법 선택2012년4월지2014년4월아원수치적78례뇌경사후억욱환자,장기수궤분위관찰조40례、대조조38례,대조조채취불서정치료,관찰조재대조조기출상연합운용대력신치료,비교량조환자림상료효、한밀이돈억욱량표(HAMD)평분이급신경공능결손(NIHSS)평분.결과 치료후총유효솔관찰조위92.50％,대조조위73.68％,량조비교차이구유통계학의의(x2=4.967,P＜0.05);치료전량조환자HAMD、NIHSS평분비교차이무통계학의의(P＞0.05),치료후량조환자HAMD、NIHSS평분균교치료전현저강저(P＜0.05),차치료후관찰조HAMD、NIHSS평분현저저우대조조(P＜0.05);불량반응발생솔관찰조위27.50％,대조조위23.68％,량조비교차이무통계학의의(x2=0.101,P＞0.05).결론 대력신연합불서정치료뇌경사후억욱증환자구유현저적림상료효,교단용불서정경가유조우환자억욱증상이급신경공능적회복,치득림상추엄운용.
Objective To investigate the clinical efficacy of Flupentixol and Melitracen combined with Fluoxetine in the treatment of depression after cerebral infarction.Methods 78 cases of depression after cerebral infarction in our hospital from April 2012 to April 2014 were randomly divided into observation group (n=40) and control group (n=38).Control group was treated with Fluoxetine,and observation group was treated with Flupentixol and Melitracen on the basis of control group.Analyzed the clinical effect,HAMD score and NIHSS score in both groups.Results After treatment,the total efficiency of observation group was 92.50％,and that of control group was 73.68％,with statistically significant difference (x 2=4.967,P＜0.05).There were no statistically significant differences in HAMD score and NIHSS score between two groups before treatment (P＞0.05);HAMD score and NIHSS score in both two groups significantly decreased after treatment (P＜0.05),HAMD score and NIHSS score in observation group after treatment were significantly lower than those in control group (P＜0.05).The incidence of adverse events was 27.50％ in observation group,23.68％ in control group,without statistically significant difference between two groups (x 2=0.101,P＞0.05).Conclusion The clinical efficacy of Flupentixol and Melitracen combined with Fluoxetine in the treatment of depression after cerebral infarction is significant,which is helpful to the recovery of depression symptoms and neurological function compared with treatment with Fluoxetine alone,worthy of clinical promotion.
